ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 312 filers reported holding ROYALTY PHARMA PLC in Q3 2023. The put-call ratio across all filers is 0.16 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $228,671,218 | -9.1% | 8,425,616 | +2.9% | 0.01% | 0.0% |
| Q2 2023 | $251,663,400 | -16.3% | 8,186,838 | -1.8% | 0.01% | -23.5% |
| Q1 2023 | $300,519,204 | -53.2% | 8,340,805 | -48.6% | 0.02% | -10.5% |
| Q4 2022 | $641,795,474 | +101.6% | 16,239,764 | +105.0% | 0.02% | -5.0% |
| Q3 2022 | $318,282,000 | -1.0% | 7,921,415 | +3.6% | 0.02% | +5.3% |
| Q2 2022 | $321,385,000 | +6.3% | 7,644,740 | -1.5% | 0.02% | +26.7% |
| Q1 2022 | $302,430,000 | +7.2% | 7,762,572 | +9.7% | 0.02% | +15.4% |
| Q4 2021 | $282,032,000 | +33.7% | 7,077,330 | +21.3% | 0.01% | +18.2% |
| Q3 2021 | $210,868,000 | +5.7% | 5,834,745 | +19.9% | 0.01% | 0.0% |
| Q2 2021 | $199,524,000 | -2.4% | 4,867,634 | +3.9% | 0.01% | -8.3% |
| Q1 2021 | $204,397,000 | +73.2% | 4,685,863 | +98.7% | 0.01% | +71.4% |
| Q4 2020 | $118,005,000 | +175.5% | 2,357,742 | +131.6% | 0.01% | +133.3% |
| Q3 2020 | $42,835,000 | +2062.3% | 1,018,194 | +2395.6% | 0.00% | – |
| Q2 2020 | $1,981,000 | – | 40,800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $244,378,000 | 79.54% |
| Vantage Consulting Group Inc | 7,862,542 | $284,152,000 | 60.85% |
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $96,878,000 | 60.36% |
| Indie Asset Partners, LLC | 701,323 | $25,346,000 | 20.53% |
| HARVARD MANAGEMENT CO INC | 7,142,856 | $258,143,000 | 15.13% |
| Bleichroeder LP | 1,115,980 | $40,332,000 | 6.55% |
| Overbrook Management Corp | 785,132 | $28,375,000 | 6.16% |
| Geo Capital Gestora de Recursos Ltd | 194,305 | $7,022,000 | 3.21% |
| Brown University | 621,759 | $22,470,000 | 3.05% |
| Graypoint LLC | 610,584 | $22,067,000 | 2.71% |